Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468
Read More
Seven things to know about COVID-19 variants in Africa
New COVID-19 variants have emerged in Africa as the continent records anew peak in infections. While virus mutations are not unusual, those that are more infectious are worrisome.Professor Francisca Mutapi, Professor in Global Health Infection and Immunity, University of Edinburgh,explains the implications of SARS-CoV-2 variants and what African countries can do to respond. Why do
Read More